Related Experiment Video
Updated: Sep 19, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer
Qizhang Li1, Xing Lu1, Yuanli Yang1
1Key Laboratory of Plant Resource Conservation and Germplasm Innovation in Mountainous Region (Ministry of Education), Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, Guizhou University, Guiyang 550025, Guizhou Province, P. R. China. silongzhang@whu.edu.cn.
Abstract:
Here we report PySAHA, a multifunctional HDAC inhibitor, which can uniquely degrade HDACs within cells via a hydrophobic tagging mechanism, and also possesses photodynamic therapeutic activity. The synergistic interplay of these dual functionalities results in potent anti-breast cancer efficacy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Inhibition of Cdk Activity

